Pasireotide in the Personalized Treatment of Acromegaly

The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some months to be fully evaluated. Considering thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Endocrinol (Lausanne)
Main Authors: Puig-Domingo, Manel, Bernabéu, Ignacio, Picó, Antonio, Biagetti, Betina, Gil, Joan, Alvarez-Escolá, Cristina, Jordà, Mireia, Marques-Pamies, Montserrat, Soldevila, Berta, Gálvez, María-Angeles, Cámara, Rosa, Aller, Javier, Lamas, Cristina, Marazuela, Mónica
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008639/
https://ncbi.nlm.nih.gov/pubmed/33796079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.648411
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados